March 30, 2016 – – TheProductLawyers.com reports on a lawsuit which has been filed against Johnson & Johnson subsidiary Janssen Pharmaceuticals regarding their new-generation, type-2 diabetes drug Invokana. The complaint was filed under case number 1:15-cv-00636 in the Southern District Of Alabama. The plaintiff filing alleges that she has linked her use of Invokana to her subsequent development of potentially life-threatening diabetic ketoacidosis condition. Additional court document details indicate that the plaintiff also alleges that she began to take the drug in December of 2014, and developed diabetic ketoacidosis shortly after this.
Diabetic ketoacidosis can cause patients to enter comatose states or even die if it remains untreated. It occurs when the body’s bloodstream contains a surplus of toxic acid (ketones). It has been noted to develop as quickly as within 24 hours, and may be able to appear without the marked warning sign of significantly high blood sugar.
The U.S. Food and Drug Administration (FDA) noted this potential concern during a public safety warning. They indicated that patients who use Invokana or other similar SGLT2 class inhibitor drugs should remain vigilant in watching for potential signs of the development of diabetic ketoacidosis. The Mayo Clinic states that these signs can include, “excessive thirst, frequent urination, nausea and vomiting, abdominal pain, shortness of breath, fruity-scented breath, and confusion.”
Additionally, the FDA has issued a public safety notice discussing the possible link between Invokana and the development of diabetic ketoacidosis among patients, and has required Janssen to make necessary changes to the product’s warning labels in order to better reflect potential side effects for patients considering the use of the drug.
This plaintiff’s lawsuit claims that she was never made aware of the potential risks of developing diabetic ketoacidosis if using Invokana. She alleges that manufacturer Janssen Pharmaceuticals (Johnson & Johnson) showed negligence by failing to effectively warn consumers regarding these possible dangerous side effects.
The attorneys of Banville Law are dedicated to keeping the public informed of all newly emerging Invokana news. To accomplish this, they sponsor TheProductLawyers.com, a resource website for the public. In addition, they are currently working to help ensure that patients who used Invokana and believe they have suffered from health complications because of their use of the drug (or other similar SGLT2 inhibitor class drugs) will be given the important opportunity to evaluate their legal rights in the matter. Those affected may be entitled to significant compensation. To help those wishing to look more deeply into their legal rights, the attorneys of Banville Law are currently offering complimentary legal consultations for qualified parties.
To request additional information, or to ask questions, please contact the attorneys of Banville Law by calling 877-671-6480.
###
Contact TheProductLawyers.com:
Banville Law
877-671-6480
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023
ReleaseID: 60008983